Solid Biosciences’ (SLDB) Stock Will Surge Over 200% From Current Levels, Says Analyst, , on October 2, 2020 at 6:56 pm

By
On October 2, 2020
Tags:

11 months ago, the U.S. Food and Drug Administration (FDA) shut down Solid Biosciences’ (SLDB) “IGNITE DMD” Phase I/II clinical trial after one of the young patients involved in the trial suffered a “serious adverse event.” Despite the patient in question recovering, no new patients suffering such serious adverse events, and the company providing the FDA with “information and measures intended to improve patient safety” and “data related to manufacturing process improvements,” the FDA declined to allow trials to resume in July, and asked Solid Biosciences to provide even more information on its trials, and on the safety measures it proposed to add to get the trials back on track.Fast forward three more months and — success!On Thursday, Solid Biosciences confirmed that the FDA has “lifted the clinical hold” on its trials, acknowledging that the company has “satisfactorily addressed all clinical hold questions.” Going forward, the company plans to remove most empty viral capsids (the protein shell that contains viral material) and limit the maximum weight of the child-patients entering its trials to 18 kilograms, so as to reduce the viral load of the SGT-001 therapy to which patients are exposed. As the name suggests, Solid Biosciences’ IGNITE DMD trials are aimed at slowing or reversing the effects of Duchenne Muscular Dystrophy (DMD), a genetic disease that causes progressive muscle degeneration and weakness mostly in young boys aged two and up (which explains the low maximum weight of trial participants). The company’s SGT-001 is a gene therapy that injects a modified virus into a patient, containing DNA coded to fix the problems that cause the disease.At least, this is what should happen in theory. The IGNITE DMD trials are designed to find out if it works in practice, and thanks to the FDA’s reconsideration, now these trials will be allowed to resume — probably in the first quarter of 2021.In a note Thursday, Chardan analyst Gbola Amusa confirmed that the FDA’s decision puts development of SGT-001 “back on course” towards addressing a $50 billion global market opportunity. If approved, the treatment will be one of only a “relatively few” gene therapies that have ever been approved for human use globally, putting Solid Biosciences in a leading position in this market. And because gene therapy products such as SGT-001 are considered “novel, complex, and relatively difficult to manufacture,” the barriers to entry in this market for competitors would be significant.The analyst views this as a “vast opportunity” — one not without risks, but one that could, if the treatment proves out, lift Solid Biosciences stock from its present price of $4 and change all the way to $12.50 or more. This new price target, by the way, is more than twice what Amusa valued the company at before the FDA’s Thursday decision, and implies 208% upside from current levels. And in fact, Amusa muses that “with progress,” the treatment “could take SLDB significantly past our updated price target of $12.50” — and notes repeatedly that in years past, Solid Biosciences stock even reached “peak highs of >$50/sh,” implying that the eventual upside could be even greater than what he’s prepared to postulate today. (To watch Amusa’s track record, click here)Overall, SLDB holds a Moderate Buy rating from the analyst consensus, based on 2 “buy,” and 1 “hold” ratings. Shares are selling for $4.06, and the average price target of $7.17 implies a 79% upside potential. (See SLDB stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

Solid Biosciences’ (SLDB) Stock Will Surge Over 200% From Current Levels, Says Analyst11 months ago, the U.S. Food and Drug Administration (FDA) shut down Solid Biosciences’ (SLDB) “IGNITE DMD” Phase I/II clinical trial after one of the young patients involved in the trial suffered a “serious adverse event.” Despite the patient in question recovering, no new patients suffering such serious adverse events, and the company providing the FDA with “information and measures intended to improve patient safety” and “data related to manufacturing process improvements,” the FDA declined to allow trials to resume in July, and asked Solid Biosciences to provide even more information on its trials, and on the safety measures it proposed to add to get the trials back on track.Fast forward three more months and — success!On Thursday, Solid Biosciences confirmed that the FDA has “lifted the clinical hold” on its trials, acknowledging that the company has “satisfactorily addressed all clinical hold questions.” Going forward, the company plans to remove most empty viral capsids (the protein shell that contains viral material) and limit the maximum weight of the child-patients entering its trials to 18 kilograms, so as to reduce the viral load of the SGT-001 therapy to which patients are exposed. As the name suggests, Solid Biosciences’ IGNITE DMD trials are aimed at slowing or reversing the effects of Duchenne Muscular Dystrophy (DMD), a genetic disease that causes progressive muscle degeneration and weakness mostly in young boys aged two and up (which explains the low maximum weight of trial participants). The company’s SGT-001 is a gene therapy that injects a modified virus into a patient, containing DNA coded to fix the problems that cause the disease.At least, this is what should happen in theory. The IGNITE DMD trials are designed to find out if it works in practice, and thanks to the FDA’s reconsideration, now these trials will be allowed to resume — probably in the first quarter of 2021.In a note Thursday, Chardan analyst Gbola Amusa confirmed that the FDA’s decision puts development of SGT-001 “back on course” towards addressing a $50 billion global market opportunity. If approved, the treatment will be one of only a “relatively few” gene therapies that have ever been approved for human use globally, putting Solid Biosciences in a leading position in this market. And because gene therapy products such as SGT-001 are considered “novel, complex, and relatively difficult to manufacture,” the barriers to entry in this market for competitors would be significant.The analyst views this as a “vast opportunity” — one not without risks, but one that could, if the treatment proves out, lift Solid Biosciences stock from its present price of $4 and change all the way to $12.50 or more. This new price target, by the way, is more than twice what Amusa valued the company at before the FDA’s Thursday decision, and implies 208% upside from current levels. And in fact, Amusa muses that “with progress,” the treatment “could take SLDB significantly past our updated price target of $12.50” — and notes repeatedly that in years past, Solid Biosciences stock even reached “peak highs of >$50/sh,” implying that the eventual upside could be even greater than what he’s prepared to postulate today. (To watch Amusa’s track record, click here)Overall, SLDB holds a Moderate Buy rating from the analyst consensus, based on 2 “buy,” and 1 “hold” ratings. Shares are selling for $4.06, and the average price target of $7.17 implies a 79% upside potential. (See SLDB stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road
#12-01 Capital Tower
Singapore 068912

New York

Coming Soon!

Dubai

Coming Soon!

Market Coverage